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Introduction
Macrophage activation syndrome (MAS) is a potentially
fatal complication of systemic juvenile idiopathic arthritis
(sJIA), whose prompt recognition and treatment are criti-
cal. However, early diagnosis of MAS is often challenging
and none of the current diagnostic criteria is satisfactory.
An international project aimed to develop a new set of
classification criteria for MAS was recently started.
Objectives
To present the results of the consensus conference that
led to the development of the new classification criteria
for MAS complicating sJIA.
Methods
28 pediatric specialists (20 rheumatologists and 8
hemato-oncologists) with expertise in MAS reviewed 428
profiles of patients with sJIA-associated MAS or with a
confusable condition (active sJIA or systemic infection).
The expert panel classified each patient as having or not
having MAS based on clinical and laboratory features at
disease onset. Using the experts’ consensus as “gold stan-
dard”, a statistician tested 982 candidate definitions,
derived from both literature and statistical analyses.
Definitions with a kappa level of agreement ≥ 0.85 were
included in the expert voting process during the consensus
conference. In a secondary analysis, experts were asked to
declare whether the change in laboratory parameters over
time was consistent or not with MAS and to rank labora-
tory tests in order of the importance of their change in the
diagnosis of MAS.
Results
After 5 rounds, experts achieved consensus on approxi-
mately 90% (391/428) of the profiles submitted. Statistical
analyses led to select 45 definitions with kappa ≥ 0.85.
During the consensus conference, 7 voting sessions were
made. Finally consensus (82%) was reached on the fol-
lowing definition: “A febrile patient with known or sus-
pected sJIA is classified as having MAS if the patient has:
ferritin >684 ng/mL and at least 2 of the following 4
laboratory abnormalities: platelets ≤ 181 x 109 /L,
aspartate aminotransferase (AST) > 48 U/L, triglycerides
> 156 mg/dL, and fibrinogen ≤ 360 mg/dL”. In the eva-
luation of change, falling platelet count, hyperferritinemia
and increased AST received the highest scores.
Conclusion
A new set of classification criteria for MAS complicating
sJIA was agreed upon in a multinational consensus confer-
ence, which gathered the leading experts in the field. The
new criteria deserve validation in a new cohort of patients
with MAS seen prospectively.
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